The therapeutic advantages of platinib compared with traditional chemotherapy

Introduction: Pratinib, as a highly selective RET inhibitor, has shown significant efficacy and good tolerability in the treatment of RET fusion-positive non-small cell lung cancer and RET-mutated medullary thyroid cancer. Compared with traditional chemotherapy, platinib provides patients with a more effective and safer treatment option.

Therapeutic advantages of platinib

has a relatively strong targeting effect and can accurately target RET mutations in tumor cells. Traditional chemotherapy drugs usually have a killing effect on normal cells and tumor cells and may cause more side effects. However, Platinib has a lower incidence of adverse events, most of which are mild to moderate. Compared with traditional chemotherapy, it has less impact on patients' quality of life. In clinical trials, the objective response rate and disease control rate of platinib in the treatment of RET fusion-positive NSCLC patients were relatively high, which was significantly better than the efficacy of traditional chemotherapy.

Platinib is still effective against some tumor cells that are resistant to traditional chemotherapy or multi-kinase inhibitors, especially those tumors that are resistant due to specific gene mutations. Patients treated with platinib show longer progression-free survival and overall survival, indicating that patients can obtain longer-term survival benefits.

Therapeutic Effects of Platinib

Platinib received accelerated approval from the FDA, and continued approval for this indication may depend on verification and description of clinical benefit in confirmatory trials. Among 87 patients who had previously received platinum-based chemotherapy, the overall response rate was 57%, the complete response rate was 5.7%, and the median duration of response could not be estimated. According to the study protocol, among 27 treatment-naive patients who were not suitable for platinum-based chemotherapy, the overall response rate was 70%, the complete response rate was 11%, and the median response duration was 9 months.

Precautions for the use of platinib

Before using the drug, it is necessary to ensure that the patient is confirmed to be RET gene fusion positive or RET mutation positive by a fully validated detection method. Platinib may cause high blood pressure, so patients should monitor their blood pressure regularly during treatment and manage it according to their doctor's recommendations. Liver function should be checked to determine baseline AST and ALT levels before starting platinib and monitored regularly during treatment. Platinib may cause harm to the fetus, so it is contraindicated in pregnant women. Women of childbearing potential should use effective non-hormonal contraceptive measures while taking Platinib and within 2 weeks after the last dose.